AUSTIN, Texas, Oct. 18, 2011 /PRNewswire/ – A new patent covering tumor suppression technologies, including the company’s lead product candidate Oncoprex™, was recently awarded to The University of Texas System by the Japan Patent Office. Patent number 4813746 pertains to the discovery that chromosome 3p21.3 genes act as cancer suppressors. The family of tumor suppressors includes TUSC2, also known as FUS1, the anti-cancer agent in Oncoprextherapy which is undergoing clinical evaluation for lung cancer patients in the U.S….
AUSTIN, TX, September 6, 2011 – Genprex, Inc., formerly known as Convergen LifeSciences, Inc., announced today that its first product candidate, the nanomolecular cancer therapy CNVN202, will be branded as Oncoprex™.
“We are establishing the Oncoprex brand in the oncology sector in recognition of our advancing development programs.